Sift Biosciences

Supercharging existing cancer therapies.

Sift Biosciences is a company in health based in Seattle, WA.

Profile

Sift is developing first- and best-in-class T-cell modulators that address a critical unmet need in oncology: most solid tumors lack immunogenic targets and remain resistant to current immunotherapies. Sift differentiates by leveraging molecular mimicry—shared genomic sequences between microbes and humans—to design highly immunogenic cancer antigen variants derived from microorganisms. This novel approach activates an otherwise untapped repertoire of pre-existing memory T-cells originally trained against microbial infections. These microbe-reactive T-cells exhibit more robust functionality compared to conventional cancer-specific T-cells. Building upon our oncology proof-of-concept, Sift is also exploring platform applications to selectively expand target-specific regulatory T cells, with the potential to restore immune tolerance in autoimmune diseases. This dual applicability further highlights the transformative potential of our mimicry-based antigen engineering approach.

As a business in health, Sift Biosciences is listed here with the public details available about it.

The business is associated with Seattle, WA.

The company is listed at the Plug and Play accelerated startup stage of development.

Website: www.siftbios.com